Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
Jyoti MayadevDmitriy ZamarinWei DengHeather LankesRoisin O'CearbhaillCarol A AghajanianRussell SchilderPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2019)
NCT03738228.